Second ground-breaking antiviral to be deployed to UK's most vulnerable

31 January 2022

Thousands of those most at-risk to COVID-19 will soon be able to access the UK’s second ground-breaking antiviral, the Department of Health and Social Care announced on Friday.

Thousands of the country’s most vulnerable will be able to access the UK’s second ground-breaking antiviral – Pfizer’s (NYSE: PFE) Paxlovid (PF-07321332+ritonavir) from Thursday February 10.

Those at highest risk who test positive for the virus – for example, people who are immunocompromized, cancer patients or those with Down’s Syndrome – could access Paxlovid directly. The Merck & Co (NYSE: MRK) antiviral molnupiravir and GlaxoSmithKline (LSE: GSK) monoclonal antibody sotrovimab are already being deployed to the highest risk patients with nearly 10,000 patients being treated to date.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK